Table 1.
EVs-related specific chemokines in tumor environment
| Tumor type | EVs type | Content of chemokines | Role of Evs | References |
|---|---|---|---|---|
| Breast cancer | MVs | CCL5, CCR6 | metastasis, proliferation and cancer cell-induced angiogenesis | [5, 47] |
| Colorectal adenocarcinoma | MVs | CCR6, CX3CR1, CCL2 | antiapoptotic effect on monocytes, AKT kinase activation,proliferation | [38, 49] |
| Gastric cancer | MVs | CCR6 | tumor progression | [52] |
| Glioblastoma | EVs | CCR8, CCL18 | proliferation and drug resistance | [56] |
| Haemophilia A | MVs | CXCL8, CXCL10, CCL2 | immunological profile | [36] |
| Leukemia | Apoptotic blebs | CCR7, CCL19 | immuno modulation | [50] |
| Exsomoes | CCL3, CCL4, CXCR4 | cell survival and drug resistance | [74] | |
| MVs | CXCR4, CCL12 | cell survival | [68] | |
| Lung carcinoma | MVs | CCR6, CX3CR1, CXCR4 | metastasis, antiapoptotic effect on monocytes, AKT kinase activation | [38, 58] |
| Exsomoes | CCL2, CCL3, CCL4, CCL5, CCL20 | antitumor immune response | [51] | |
| Lymphoma | Exosomes | CCL2, CCL7 | macrophage recruitment | [42] |
| Melanoma | Exosomes | CCL2, CCL3, CCL4, CCL5, CCL7, CCL20 | macrophage recruitment, antitumor immune response | [42, 51] |
| MVs | CCL2 | inhibi ttumor proliferation | [49] | |
| Pancreatic adenocarcinoma | MVs | CCR6, CX3CR1, CCL2, CCL3, CCL4, CCL5, CXCL8 | anti-apoptosis, AKT kinase activation, angiogenesis | [38, 39] |
| Prostate cancer | Oncosomes | CXCL12 | oncogenic signaling | [23] |